import
phosphonoamid
prodrug
protid
acycl
nucleosid
phosphon
anp
highlight
approv
tenofovir
alafenamid
fumar
treatment
hiv
hbv
infect
present
paper
report
expedi
onepot
twostep
synthesi
allyl
phosphonoamid
diamid
offer
time
save
strategi
compar
literatur
method
use
substrat
cross
metathesi
reaction
alkenyl
functionalis
thymin
uracil
nucleobas
report
anp
prodrug
synthes
via
methodolog
evalu
antivir
activ
dna
rna
virus
anticip
use
aryloxi
moieti
capabl
confer
antivir
activ
among
seri
otherwis
inact
uracil
protid
scheme
protid
synthesi
via
crossmetathesi
reagent
condit
allyl
phosphonoamid
equiv
olefin
equiv
ch
cl
reflux
temperatur
hoveydagrubb
gener
catalyst
mol
ad
h
reaction
sonic
h
e
pileggi
et
al
protid
approach
pioneer
chri
mcguigan
group
power
technolog
aim
optim
intracellular
drug
deliveri
circumv
metabol
bottleneck
activ
nucleosidebas
antivir
anticanc
drug
last
year
technolog
display
great
deal
success
antivir
field
two
compound
market
phosphoramid
sofosbuvir
approv
hcv
infect
phosphonoamid
tenofovir
alafenamid
fumar
taf
approv
treatment
hiv
later
hbv
infect
fig
sever
protid
enter
clinic
trial
mani
other
preclin
evalu
either
antivir
anticanc
drug
given
tremend
import
phosphor
n
oamid
prodrug
antivir
arena
beyond
approv
sofosbuvir
taf
applic
protid
technolog
grown
dramat
start
show
promis
result
therapeut
area
well
sever
effici
procedur
synthes
phosphoroamid
nucleosid
phosphonoamid
cognat
class
especi
acycl
nucleosid
phosphon
anp
lack
plethora
synthet
methodolog
anp
play
key
role
treatment
viral
infect
class
compound
regard
one
signific
group
drug
antivir
field
discov
almost
year
ago
great
wealth
research
dedic
develop
effici
synthet
methodolog
result
great
varieti
anp
new
structur
offer
potenti
discoveri
effect
drug
varieti
infecti
diseas
includ
antiparasit
antimicrobi
antitubercol
medicin
among
synthet
strategi
quit
recent
agrofoglio
group
elabor
novel
effici
straightforward
synthesi
substitut
anp
via
olefin
crossmetathesi
although
structureact
relationship
sar
studi
acycl
nucleosid
clarifi
pharmacophor
model
introduct
rigid
structur
element
doubl
bond
prove
extrem
import
antivir
activ
precis
transalken
skeleton
abl
mimic
threedimension
geometri
ribos
ring
maintain
also
electron
contribut
similar
one
provid
oxygen
consider
evid
transalkenyl
acycl
nucleotid
motif
strong
affin
recombin
human
thymidyl
kinas
htmpk
activ
site
respons
nucleotid
phosphoryl
consequ
correl
antivir
activ
interestingli
agrofoglio
group
employ
olefin
crossmetathesi
methodolog
also
direct
synthesi
vast
array
unsatur
anp
analogu
includ
bispom
bispoc
alkoxyest
prodrug
although
adopt
differ
procedur
group
extend
rang
prodrug
e
synthesis
protid
bisamid
deriv
studi
show
protid
technolog
abl
broaden
spectrum
antivir
activ
compar
phosphat
prodrug
approach
howev
discov
methodolog
suffer
limit
linear
olefin
must
employ
trisubstitut
alkenyl
deriv
observ
format
trace
desir
protid
find
prompt
us
investig
possibl
use
crossmetathesi
direct
synthesi
unsatur
branch
anp
phosphonoamid
time
start
investig
applic
procedur
synthesi
protid
yet
report
howev
prepar
manuscript
paper
report
use
cross
metathesi
synthesi
protid
deriv
linear
e
nucleosid
scaffold
publish
prodrug
describ
work
belong
famili
compound
previous
report
us
inde
antivir
profil
agreement
publish
result
present
articl
would
like
report
effect
improv
methodolog
synthesi
allyl
phosphonoamid
applic
olefin
crossmetathesi
synthesi
anp
protid
also
anticip
twostep
onepot
methodolog
also
appli
synthesi
symmetr
allyl
phosphonodiamid
compar
recent
publish
procedur
synthet
strategi
present
advantag
believ
merit
consider
research
began
synthesi
aryloxi
allylphosphonoamid
synthon
literatur
procedur
avail
long
tediou
multistep
sequenc
base
experi
applic
holi
onepot
procedur
direct
synthesi
phosphonodiamid
envisag
protocol
could
use
get
access
desir
synthon
start
commerci
avail
dimethyl
allylphosphon
scheme
methodolog
alreadi
adapt
laboratori
synthesi
adefovir
tenofovir
phosphonoamid
prodrug
recent
prepar
e
pyrimidin
protid
briefli
commerci
dimethyl
allylphosphon
convert
correspond
silyl
ester
reaction
excess
bromotrimethylsilan
equival
due
hydrolyt
instabl
ester
isol
immedi
dissolv
mixtur
pyridineet
n
treat
lalanin
isopropyl
ester
hydrochlorid
equival
excess
equival
premad
solut
pph
equival
equival
pyridin
h
crude
mixtur
show
presenc
either
desir
product
phosphonodiamid
compound
base
experi
almost
invari
form
attribut
lack
reactiv
decomposit
disilyl
ester
caus
releas
hydrobrom
acid
gener
hydrolysi
excess
tmsbr
use
pleasingli
attempt
reaction
presenc
equival
acid
scaveng
format
desir
product
observ
p
nmr
lcm
analysi
crude
mixtur
isol
flash
chromatographi
excel
yield
tabl
entri
quit
surprisingli
evid
side
reaction
bromin
doubl
bond
format
phosphonodiamid
observ
methodolog
prepar
six
differ
allyl
phosphon
analogu
varieti
aryloxi
group
introduc
combin
two
differ
amino
acid
ester
lalanin
isopropyl
benzyl
ester
tabl
appreci
method
work
well
aryl
alcohol
differ
steric
requir
particular
abl
prepar
allyl
phosphonoamid
bear
entri
tabl
shown
impart
remark
antivir
activ
compound
previou
seri
procedur
short
effici
repres
improv
literatur
method
account
overal
yield
four
step
allyl
phosphonoamid
hand
began
synthesi
e
pyrimidin
select
partner
crossmetathesi
reaction
nucleosid
bispom
prodrug
origin
prepar
agrofoglio
colleagu
found
latest
moder
activ
felin
herp
viru
fhv
felin
corona
viru
fcov
consid
protid
alkenyl
pyrimidin
linear
e
doubl
bond
shown
improv
antivir
activ
broad
antivir
spectrum
compar
correspond
bispom
deriv
interest
investig
whether
protid
branch
alkenyl
pyrimidin
might
effect
therefor
synthesis
thymin
uracil
deriv
report
scheme
amino
acid
ester
hydrochlorid
equiv
arylalcohol
equiv
et
n
equiv
equiv
pph
equiv
pyridin
h
alkenyl
deriv
hand
posit
investig
crossmetathesi
condit
aryloxi
allylphosphonoamid
synthon
olefin
model
reaction
first
employ
cm
condit
develop
use
agrofoglio
synthesi
correspond
bispom
alkenyl
deriv
expect
obtain
mixtur
ez
isom
desir
compound
afford
yield
entri
tabl
isom
isol
prepar
revers
phasehplc
configur
confirm
noesi
experi
homodim
form
along
ez
deriv
attempt
improv
reaction
outcom
use
differ
catalyst
hoveydagrubb
gener
catalyst
grubb
gener
catalyst
b
grubb
catalyst
c
fail
provid
similar
lower
yield
almost
ident
ez
ratio
entri
tabl
sinc
catalyst
result
best
term
product
homodim
ratio
screen
conduct
keep
catalyst
prolong
reaction
time
entri
tabl
result
slightli
increas
yield
howev
improv
addit
catalyst
entri
tabl
condit
differ
report
agrofoglio
recent
paper
e
pyrimidin
protid
form
via
cross
metathesi
water
use
solvent
use
condit
prepar
differ
aryloxi
phosphonoamid
thymin
uracil
deriv
desir
compound
isol
moder
yield
scheme
tabl
case
zisom
also
isol
yield
scheme
pleas
outcom
procedur
expand
versatil
methodolog
decid
use
reaction
condit
prepar
symmetr
phosphonodiamid
briefli
desir
bisamid
intermedi
obtain
yield
treat
allyl
phosphon
excess
tmsbr
presenc
equival
lutidin
result
silyl
diester
react
excess
equival
lalanin
isopropyl
hydrochlorid
scheme
compound
subject
olefin
crossmetathesi
reaction
compound
condit
report
scheme
phosphonodiamid
obtain
mixtur
e
z
isom
eisom
isol
yield
purif
prepar
revers
phasehplc
sinc
ruthenium
catalyst
use
synthesi
interest
measur
residu
amount
final
sampl
icpm
experi
compound
show
ruthenium
content
protid
deriv
synthesis
evalu
panel
dna
rna
virus
previous
describ
none
compound
activ
herp
simplex
ko
herp
simplex
g
thymidin
kinas
defici
herp
simplex
ko
acyclovirresist
strain
tk
vaccinia
viru
vv
human
coronaviru
hel
cell
viru
vesicular
stomat
viru
vsv
respiratori
syncyti
viru
rsv
hela
cell
influenza
influenza
influenza
b
mdck
cell
shown
tabl
thymin
deriv
show
weak
antivir
activ
varicellazost
viru
vzv
tk
tk
human
cytomegaloviru
hcmv
strain
davi
strain
ec
rang
wherea
uracil
deriv
mostli
inact
virus
except
ec
vzv
tk
ec
vzv
tk
interestingli
uracil
deriv
bear
aryl
moieti
result
slightli
activ
vzv
tk
tkstrain
confirm
biolog
potenti
promoieti
specif
inform
ld
report
literatur
phenol
howev
previou
studi
shown
vitro
assay
cc
valu
anp
protid
bear
moieti
compar
cc
valu
bear
phenol
also
observ
present
studi
remark
z
isom
isol
e
f
show
extent
antivir
activ
davi
hcmv
strain
furthermor
compound
found
weakli
activ
sindbi
viru
sinv
coxsacki
viru
punta
toro
viru
ptv
yellow
fever
viru
yfv
vero
cell
ec
valu
rang
none
compound
show
signific
cytotox
abl
inhibit
vzv
protid
allylphosphon
pyrimidin
show
broader
antivir
activ
correspond
bispom
prodrug
previous
report
agrofoglio
contrari
linear
alkenyl
deriv
show
higher
ec
vzv
perform
better
branch
suggest
substitut
doubl
bond
detriment
antivir
activ
metabol
activ
phosphonoamid
follow
twoenzymat
step
involv
activ
phosphoroamid
although
use
aryloxi
group
protid
quit
recent
shown
metabol
activ
carboxypeptidas
previou
studi
prove
stabil
class
compound
perform
stabil
assay
compound
rat
human
sera
indic
suitabl
pharmacokinet
profil
test
phosphonoamid
halflif
higher
h
fig
conclus
success
report
one
pottwo
step
synthesi
famili
allyl
phosphonoamid
methodolog
import
improv
recent
report
strategi
allow
synthesi
substrat
shorter
synthet
sequenc
overal
higher
yield
also
extend
protocol
synthesi
hitherto
unknown
allyl
phosphonodiamid
also
prove
synthon
capabl
undergo
alken
crossmetathesi
alkenyl
function
uracil
thymin
nucleobas
although
yield
need
optim
especi
case
phosphonodiamid
phosphonoamid
prodrug
evalu
biolog
activ
panel
dna
rna
virus
none
compound
prepar
show
signific
cytotox
protid
allylphosphon
pyrimidin
show
broader
antivir
activ
correspond
bispom
prodrug
vzv
infect
cell
also
demonstr
introduct
moieti
protid
scaffold
capabl
increas
antivir
activ
prodrug
final
eisom
show
biolog
activ
also
z
isom
isol
e
f
show
extent
antivir
activ
davi
hcmv
strain
studi
direct
optim
cross
metathesi
procedur
especi
allyl
phosphonoamid
current
progress
laboratori
solvent
use
anhydr
use
suppli
sigmaaldrich
commerci
avail
reagent
suppli
either
tabl
substitut
pattern
isol
yield
phosphonoamid
bz
h
yield
determin
isol
purifi
compound
see
experiment
part
detail
scheme
synthesi
symmetr
allyl
phosphonodiamid
reagent
condit
tmsbr
equiv
equiv
ch
cn
rt
h
ii
benzyloxylalanin
hydrochlorid
equiv
et
n
equiv
equival
pph
equiv
pyridin
h
iii
n
equiv
hoveydagrubb
gener
catalyst
mol
ch
cl
sonic
h
reflux
temperatur
sigmaaldrich
fisher
use
without
purif
nucleosid
solid
reagent
dri
sever
hour
high
vacuum
prior
use
analyt
thinlay
chromatographi
tlc
precoat
aluminiumback
plate
mm
thick
suppli
e
merck
ag
darmstadt
germani
use
develop
ascend
elut
method
prepar
thinlay
chromatographi
prep
tlc
prepar
tlc
plate
cm
cm
purchas
merck
solvent
evapor
compound
detect
quench
fluoresc
nm
upon
irradi
uv
lamp
column
chromatographi
purif
carri
mean
automat
biotag
isolera
one
fraction
contain
product
identifi
tlc
pool
ec
effect
concentr
concentr
requir
inhibit
viral
induc
cytopath
effect
hcmv
sinv
coxsacki
viru
ptv
yfv
plaqu
format
vzv
mcc
minim
cytotox
concentr
caus
microscop
alter
cell
morpholog
solvent
remov
vacuo
h
p
c
nmr
spectra
record
bruker
avanc
spectromet
mhz
mhz
mhz
respect
autocalibr
deuter
solvent
refer
peak
case
h
c
nmr
h
po
p
nmr
experi
p
c
nmr
spectra
protondecoupl
chemic
shift
given
part
per
million
ppm
coupl
constant
j
measur
hertz
hz
follow
abbrevi
use
assign
nmr
signal
singlet
doublet
triplet
q
quartet
multiplet
bs
broad
singlet
dd
doublet
doublet
ddd
doublet
doublet
doublet
dt
doublet
triplet
assign
signal
h
nmr
c
nmr
done
base
analysi
coupl
constant
addit
twodimension
experi
cosi
hsqc
analyt
highperform
liquid
chromatographi
hplc
analysi
perform
use
spectra
system
scm
mm
mm
column
varian
prostar
system
lcworkstationvarian
prostar
lc
detector
prepar
hplc
perform
varian
prostar
pursuit
xr
mm
column
low
highresolut
mass
spectrometri
perform
bruker
dalton
microtoflc
system
atmospher
pressur
ioniz
electron
spray
mass
spectroscopi
posit
mode
puriti
final
compound
e
f
confirm
hplc
analysi
round
bottom
flask
argon
atmospher
eq
trimethylsilyl
bromid
tmsbr
eq
ad
solut
dimethyl
allylphosphon
eq
anhydr
acetonitril
mlmmol
allylphosphon
mixtur
stir
h
room
temperatur
volatil
evapor
without
contact
air
flask
charg
dri
aminoacid
ester
hydrochlorid
eq
dri
arylalcohol
eq
dri
triethylamin
eq
dri
pyridin
mlmmol
allylphosphon
heat
obtain
homogen
solut
mixtur
ad
solut
eq
triphenylphosphin
eq
dri
pyridin
ml
mmol
allylphosphon
argon
atmospher
result
mixtur
stir
h
evapor
volatil
residu
purifi
biotag
isolera
one
prepar
accord
standard
procedur
synthesi
allylphosphonoamid
use
dimethyl
allylphosphon
mg
mmol
ml
mmol
tmsbr
ml
mmol
anhydr
acetonitril
ml
second
step
use
dri
isopropyloxylalanin
hydrochlorid
mg
mmol
dri
g
mmol
dri
triethylamin
ml
mmol
dri
pyridin
ml
solut
g
mmol
triphenylphosphin
g
mmol
dri
pyridin
ml
evapor
mixtur
purifi
biotag
isolera
one
g
snap
cartridg
ultra
mlmin
gradient
eluent
system
etoachexan
afford
titl
compound
yellow
oil
mg
r
f
etoachexan
prepar
accord
standard
procedur
synthesi
allylphosphonoamid
use
dimethyl
allylphosphon
mg
mmol
ml
mmol
tmsbr
ml
mmol
anhydr
acetonitril
ml
second
step
use
dri
benzyloxylalanin
hydrochlorid
mg
mmol
dri
g
mmol
dri
triethylamin
ml
mmol
dri
pyridin
ml
solut
g
mmol
triphenylphosphin
g
mmol
dri
pyridin
ml
evapor
mixtur
purifi
biotag
isolera
one
g
snap
cartridg
ultra
mlmin
gradient
eluent
system
etoachexan
afford
titl
compound
yellow
oil
g
r
f
etoachexan
ml
second
step
use
dri
isopropyloxylalanin
hydrochlorid
mg
mmol
dri
phenol
g
mmol
dri
triethylamin
ml
mmol
dri
pyridin
ml
solut
g
mmol
triphenylphosphin
g
mmol
dri
pyridin
ml
evapor
mixtur
purifi
biotag
isolera
one
g
snap
cartridg
ultra
mlmin
gradient
eluent
system
etoachexan
afford
titl
compound
yellow
oil
mg
r
f
etoachexan
round
bottom
flask
argon
atmospher
solut
nucleobas
eq
anhydr
acetonitril
mlmmol
nucleobas
ad
bsa
eq
mixtur
reflux
clear
solut
observ
usual
min
eq
nai
eq
tmscl
eq
ad
reaction
mixtur
solut
reflux
h
evapor
reduc
pressur
residu
dissolv
etoac
wash
nahco
aqueou
satur
solut
na
aqueou
satur
solut
h
brine
dri
mgso
result
mixtur
evapor
residu
purifi
biotag
isolera
one
prepar
accord
standard
procedur
b
synthesi
n
use
thymin
g
mmol
bsa
ml
mmol
ml
mmol
nai
g
mmol
tmscl
ml
mmol
anhydr
acetonitril
ml
work
evapor
compound
obtain
pale
yellow
solid
quantit
yield
prepar
accord
standard
procedur
b
synthesi
n
use
uracil
g
mmol
bsa
ml
mmol
ml
mmol
nai
g
mmol
tmscl
ml
mmol
anhydr
acetonitril
ml
work
evapor
mixtur
purifi
biotag
isolera
one
g
snap
cartridg
ultra
mlmin
gradient
eluent
system
etoachexan
afford
titl
compound
pale
yellow
solid
solut
oaryl
lalanineest
allylphosphon
eq
n
eq
dri
ch
cl
mlmmol
allylphosphon
ad
hoveydagrubb
gener
catalyst
mol
catalyst
ad
three
equal
portion
mol
h
cours
reaction
solut
sonic
argon
atmospher
h
volatil
evapor
residu
purifi
biotag
isolera
one
also
revers
phase
chromatographi
necessari
gain
pure
final
product
prepar
accord
standard
procedur
c
synthesi
anp
protid
use
isopropyloxylalanin
allylphosphon
mg
n
mg
hoveydagrubb
gener
catalyst
mol
dri
ch
cl
ml
evapor
crude
purifi
biotag
isolera
one
g
snap
cartridg
ultra
mlmin
gradient
eluent
system
meohch
cl
afford
mixtur
e
z
isom
two
isom
separ
revers
biotag
isolera
one
g
snap
cartridg
mlmin
isocrat
eluent
system
ch
cnh
afford
titl
compound
e
pale
yellow
foami
solid
mg
r
f
ch
cl
meoh
prephplc
also
z
isom
isol
pale
yellow
foami
solid
mg
prepar
accord
standard
procedur
c
synthesi
anp
protid
use
benzyloxylalanin
allylphosphon
mg
n
mg
mmol
hoveydagrubb
gener
catalyst
mol
dri
ch
cl
ml
evapor
crude
purifi
biotag
isolera
one
g
zip
cartridg
kpsil
mlmin
gradient
eluent
system
meohch
cl
afford
mixtur
e
z
isom
two
isom
separ
prephplc
ml
min
isocrat
elut
system
ch
mol
dri
ch
cl
ml
evapor
crude
purifi
biotag
isolera
one
g
snap
cartridg
ultra
mlmin
gradient
eluent
system
cl
afford
mixtur
e
z
isom
two
isom
separ
prephplc
mlmin
isocrat
elut
system
ch
prephplc
also
z
isom
isol
pale
yellow
foami
solid
mg
mol
dri
ch
cl
ml
evapor
crude
purifi
biotag
isolera
one
g
snap
cartridg
ultra
mlmin
gradient
eluent
system
cl
afford
mixtur
e
z
isom
two
isom
separ
revers
biotag
isolera
one
g
snap
cartridg
mlmin
isocrat
eluent
system
ch
hoveydagrubb
gener
catalyst
mol
dri
ch
cl
ml
evapor
crude
purifi
biotag
isolera
one
g
snap
cartridg
ultra
mlmin
gradient
eluent
system
meohch
cl
afford
mixtur
e
z
isom
two
isom
separ
prephplc
mlmin
isocrat
elut
system
ch
hoveydagrubb
gener
catalyst
mol
dri
ch
cl
ml
evapor
crude
purifi
biotag
isolera
one
g
zip
cartridg
kpsil
mlmin
gradient
eluent
system
meohch
cl
afford
mixtur
e
z
isom
two
isom
separ
prephplc
mlmin
isocrat
elut
system
ch
cnh
min
afford
titl
compound
pale
yellow
foami
solid
mg
r
f
ch
cl
meoh
prepar
accord
standard
procedur
c
synthesi
anp
protid
use
ophenyl
isopropyloxylalanin
allylphosphon
mg
n
mg
mmol
hoveydagrubb
gener
catalyst
mol
dri
ch
cl
ml
evapor
crude
purifi
biotag
isolera
one
g
snap
cartridg
ultra
mlmin
gradient
eluent
system
meoh
ch
cl
afford
mixtur
e
z
isom
two
isom
separ
prephplc
mlmin
gradient
elut
system
ch
cnh
min
afford
titl
compound
pale
yellow
foami
solid
mg
r
f
ch
cl
meoh
prepar
accord
standard
procedur
c
synthesi
anp
protid
use
ophenyl
benzyloxylalanin
allylphosphon
mg
n
mg
mmol
hoveydagrubb
gener
catalyst
mol
dri
ch
cl
ml
evapor
crude
purifi
biotag
isolera
one
g
snap
cartridg
ultra
mlmin
gradient
eluent
system
cl
afford
mixtur
e
z
isom
two
isom
separ
prephplc
mlmin
isocrat
elut
system
ch
